Sublingual solutions

-  Print

Phases and duration of treatment

Prescribed by an allergy specialist, treatment is taken at home in the morning, preferably before breakfast by placing dosed allergen extracts under the tongue. The treatment should be kept under the tongue for two minutes before swallowing.

The initiation phase and the maintenance phase  

  • The first phase called the "initial treatment" aims at administering increasing doses of allergenic extract.  During the first days, starting with a low dose of the allergen in question, the dose of the allergen administered is increased until the patient’s best tolerated maximum dose is reached.
  • The second phase, called the “maintenance phase”, can then start. The patient’s best tolerated maximum dose reached at the end of the 1st phase is then administered at regular times (in accordance with the administration route and patient sensitivity) for a period varying between 3 and 5 years or during several pollen seasons.

Initiation phase

Maintenance phase

Seasonal allergies

11 days with progressive dose increase 

3 to 5  successive seasons

Perennial allergies

11 days with progressive dose increase

3 to 5 years

Indications and contra-indications

Indications:

  • Allergic diseases where the sensitisation mechanism is IgE-dependant and the allergen(s) well identified ;
  • Marked clinical discomfort requiring daily symptomatic treatment for long periods of time ;
  • Partially effective symptomatic treatments or causing adverse events ;
  • Ineffective or difficult to implement eviction methods ;
  • Intolerance  to injectable allergen immunotherapy ;
  • Rhinitis and/or potentially severe asthma, or likely to worsen in the mid to long term ;
  • Motivated and compliant patient ;
  • Adults and children (> 5 years).

Contra-indications

  • Hypersensitivity to one of the excipients (see list of excipients) ;
  • Auto-immune disease, immune complex disease, immunodeficiency disease ;
  • Malignant disease or tumour ;
  • Severe or poorly controlled asthma (FEVI ≤ 70%) ;
  • Patient taking beta-blockers (including local applications e.g.: eye drops) ;
  • Inflammatory disorders of the mouth associated with severe symptoms such as oral lichen planus with severe ulceration or mycosis of the oral mucosa.